Tapinarof (VTAMA) for psoriasis

VTAMA (tapinarof) cream is an aryl hydrocarbon receptor (AhR) agonist - a steroid-free medicine that works through a different pathway than a steroid or a calcineurin inhibitor. Think of the AhR as a built-in control panel inside skin cells for inflammation and skin-barrier repair; tapinarof turns dials on that panel toward calm. The label itself is honest that the exact mechanisms by which this clears psoriasis are not fully mapped.⌁ Evidence

The FDA approved VTAMA cream 1% for plaque psoriasis in adults. The label sets no site restriction and no limit on how long you can use it continuously. That is unlike a steroid, which caps continuous use because of skin-thinning risk. People I have heard from worry most that a steroid will thin their skin or stop working. AAD patient education confirms it in plain terms: it can be applied anywhere on the body, including the face. It is topical only, not for oral, eye, or intravaginal use, and it is not approved for psoriasis in children.⌁ Evidence⌁ Evidence

You apply it once a day. Two identical trials that led to approval, PSOARING 1 and PSOARING 2, checked results at 12 weeks using PGA success. That means a score of clear or almost clear, with at least a 2-grade improvement from baseline. 36% of people on tapinarof reached that mark in PSOARING 1 (versus 6% on vehicle cream alone), and 40% did in PSOARING 2 (versus 6% on vehicle). Among trial participants who cleared completely and then stopped treatment, skin stayed clear for a median of 114 days (about 16 weeks) before it started to worsen again. The label calls this a remittive effect.⌁ Evidence⌁ Evidence

In the trials that led to approval, the most common effect was folliculitis: inflamed hair follicles, which can look like small pimple-like bumps. It happened in 20% of people on tapinarof versus 1% on vehicle. Other reported effects: nasopharyngitis (11% vs 9%), contact dermatitis (7% vs 1%), headache (4% vs 1%), itching (3% vs 1%), and influenza (2% vs 1%). There is no boxed warning and no contraindication listed on the label. AAD describes the most common side effect in plain terms as a skin reaction. Call your dermatologist about any reaction that does not ease with continued use.⌁ Evidence⌁ Evidence

I could not capture a live retail price; GoodRx returned an access-blocked response on 2026-09-08. So I went to the manufacturer instead. The MyVTAMA savings card can bring the cost to as little as $0 per fill (capped at $35) for people with commercial insurance. That offer explicitly does not apply if any part of the prescription claim is reimbursable by a government program (Medicare, Medicaid, or similar). For people who are uninsured and cannot afford their medicine, the separate Organon Patient Assistance Program is an option. It can provide the medicine at no cost for up to a year at a time. Eligibility is subject to a household-income limit of 250% of the Federal Poverty Level. No generic version exists yet.⌁ Evidence⌁ Evidence

No reader has sent me a first-hand account of tapinarof yet. Until someone does, here is what the label and the studies say about living with it.⌁ Evidence

Keep a simple, dated record: which areas you are treating and when you started. Add a same-conditions photo (same light, distance, and angle) each time. The approval trials checked results at 12 weeks, a reasonable point to compare your own dated photos against. If your skin clears and you and your dermatologist decide to pause treatment, note the date you stopped. The trials found clearing lasted a median of about 16 weeks after stopping among people who had cleared completely. A dated record helps you and your dermatologist notice if and when it starts to return.⌁ Evidence